단일 광자 방출 단층촬영(SPECT) 시장 예측(2026-2032년)

The Single Photon Emission Computed Tomography Market is projected to grow by USD 3.02 billion at a CAGR of 4.09% by 2032.

Single Photon Emission Computed Tomography (SPECT) remains a core nuclear medicine imaging modality for functional assessment of physiology, particularly in cardiology, oncology, neurology, endocrinology, and infection/inflammation imaging. By detecting gamma photons emitted from radiotracers administered to patients, SPECT enables clinicians to evaluate organ perfusion, receptor expression, bone metabolism, myocardial viability, cerebral blood flow, and other molecular-level processes that are not fully captured by anatomical imaging alone. The modality's established clinical utility is supported by widely used radiopharmaceuticals, standardized acquisition protocols, and broad integration into hospital imaging departments, outpatient diagnostic centers, and academic medical institutions.

The current SPECT landscape is being shaped by demand for earlier disease detection, more precise therapy planning, and efficient management of chronic conditions such as coronary artery disease, neurodegenerative disorders, thyroid disease, and metastatic bone disease. Hybrid SPECT/CT systems have strengthened diagnostic confidence by combining functional information with anatomical localization, while advances in detector technology, reconstruction algorithms, workflow automation, and quantitative imaging are improving image quality, scan efficiency, and reproducibility. Regulatory emphasis on radiation safety, radiopharmaceutical quality, and evidence-based appropriate use continues to influence adoption and protocol design. As healthcare systems prioritize value-based care, SPECT is increasingly evaluated not only for diagnostic accuracy but also for its ability to guide treatment decisions, reduce unnecessary downstream procedures, and support longitudinal disease monitoring.

Transformative Shifts in the SPECT Landscape

The SPECT ecosystem is undergoing transformative shifts driven by technology modernization, evolving clinical pathways, and the broader movement toward precision medicine. Hybrid SPECT/CT has become a preferred configuration in many advanced imaging settings because anatomical co-registration improves lesion localization, attenuation correction, and interpretation confidence. Dedicated cardiac SPECT systems, solid-state detector platforms, and optimized collimator designs are supporting shorter acquisition times and improved sensitivity, which can enhance patient throughput and comfort when implemented within validated clinical protocols.

Radiopharmaceutical innovation is also redefining SPECT's role. Established tracers continue to anchor routine practice, while research and clinical translation are expanding applications in neuroendocrine tumors, parathyroid imaging, infection localization, dopamine transporter imaging, sentinel node mapping, and targeted radionuclide therapy planning. At the same time, healthcare providers are focusing on dose optimization through appropriate-use criteria, patient-specific protocols, and iterative reconstruction methods that support diagnostic-quality images with radiation-conscious workflows. Operationally, imaging departments are adopting digital scheduling, remote quality review, structured reporting, and integrated picture archiving to reduce variability and improve reporting efficiency. These shifts are positioning SPECT as a more connected, quantitative, and clinically actionable diagnostic tool rather than a standalone imaging procedure.

Cumulative Impact of Artificial Intelligence on SPECT

Artificial intelligence is creating a cumulative impact across the SPECT value chain, from patient preparation and acquisition to reconstruction, interpretation, reporting, and quality assurance. AI-enabled reconstruction and denoising techniques are being studied and implemented to improve image quality, reduce artifacts, and support lower-dose or shorter-duration imaging protocols where clinically appropriate. Machine learning models can assist in attenuation correction, motion correction, segmentation, lesion detection, and quantitative parameter extraction, helping reduce reader variability and improve consistency in high-volume imaging environments.

In cardiac SPECT, AI is increasingly relevant for automated perfusion assessment, ischemia evaluation, ventricular function analysis, and risk stratification when validated against clinical outcomes and expert interpretation. In neurology and oncology, AI-based pattern recognition may support more reproducible assessments of tracer distribution, disease progression, and treatment response. The most important near-term impact is likely to come from workflow augmentation rather than autonomous diagnosis: automated protocol checks, image quality alerts, standardized measurements, and structured reporting can help nuclear medicine teams operate more efficiently while maintaining physician oversight. However, responsible deployment requires transparent validation, data governance, cybersecurity controls, bias monitoring, regulatory compliance, and integration with existing clinical systems. Institutions adopting AI in SPECT must ensure that algorithms are trained and evaluated on representative datasets and that performance is continuously monitored in real-world practice.

Key Regional Insights for SPECT

Asia-Pacific is witnessing rising clinical utilization of SPECT as healthcare infrastructure expands, cancer and cardiovascular disease screening programs mature, and tertiary hospitals invest in hybrid nuclear medicine capabilities. China, India, Japan, South Korea, and Australia are central to regional development due to their advanced hospital networks, academic nuclear medicine activity, and growing demand for cardiac, oncology, and neurological imaging. Japan and South Korea demonstrate strong adoption of advanced imaging workflows, while China and India are expanding access across large patient populations through public and private healthcare investments. In Southeast Asia, SPECT growth is closely tied to urban hospital modernization, specialist training, and improving radiopharmaceutical logistics.

North America remains one of the most mature SPECT environments, supported by established nuclear cardiology practices, broad reimbursement structures, robust regulatory oversight, and strong use of hybrid imaging in hospitals and outpatient centers. The United States is particularly important for protocol standardization, cardiac SPECT utilization, AI-enabled workflow adoption, and clinical research, while Canada emphasizes quality assurance, radiation safety, and access across provincial healthcare systems. Latin America is advancing through expanded diagnostic imaging capacity in Brazil, Mexico, and other major economies, although access can vary substantially between urban centers and underserved regions. Europe benefits from structured nuclear medicine guidelines, strong academic collaboration, and widespread use of SPECT/CT in oncology, endocrinology, musculoskeletal imaging, neurology, and cardiology, with Germany, France, Italy, Spain, and the United Kingdom supporting diversified clinical application.

The Middle East is strengthening SPECT capabilities through investment in specialty hospitals, cancer centers, and cardiovascular care programs, especially in countries with advanced tertiary-care infrastructure. Adoption is supported by efforts to reduce outbound medical travel and improve local diagnostic capabilities. Africa presents a more heterogeneous landscape, with SPECT services concentrated in larger urban hospitals and academic centers. Key priorities across the continent include workforce development, radiopharmaceutical availability, equipment maintenance, radiation safety governance, and equitable access to diagnostic imaging.

Key Group Insights for SPECT

ASEAN countries are increasingly integrating SPECT into tertiary-care pathways as urban healthcare systems expand and demand rises for cardiac, oncology, neurology, bone, and endocrine imaging. The region's progress is shaped by uneven access to nuclear medicine specialists, differences in reimbursement, and the need for reliable radiopharmaceutical supply chains across island and cross-border geographies. GCC countries are advancing SPECT adoption through high-acuity hospital infrastructure, national health transformation programs, and investment in oncology and cardiovascular services. Their emphasis on advanced diagnostics, accreditation, and specialist care supports the integration of hybrid SPECT/CT systems within comprehensive imaging departments.

The European Union provides a highly structured environment for SPECT through harmonized radiation protection principles, clinical practice guidelines, cross-border research networks, and strong emphasis on quality assurance. EU healthcare systems are increasingly focused on appropriate utilization, dose optimization, and evidence-based imaging pathways. BRICS countries show diverse but strategically significant SPECT development: China and India are expanding capacity to serve large populations; Brazil and Russia maintain important nuclear medicine capabilities in major cities; and South Africa plays a central role in African nuclear medicine expertise and training. Within the G7, SPECT utilization is supported by advanced clinical guidelines, established reimbursement models, high levels of imaging infrastructure, and significant academic research activity. NATO member countries, many of which overlap with advanced European and North American health systems, benefit from mature hospital networks, standardized quality systems, and strong emphasis on healthcare resilience, imaging interoperability, and regulated use of radioactive materials.

Key Country Insights for SPECT

The United States represents a highly developed SPECT environment with extensive nuclear cardiology usage, advanced hybrid imaging capabilities, and growing interest in AI-supported workflow optimization. Canada emphasizes standardized clinical practice, radiation safety, and equitable access across provincial systems, while Mexico is expanding SPECT capacity in major metropolitan hospitals and private diagnostic networks. Brazil is a leading Latin American contributor to nuclear medicine practice, particularly in oncology, cardiology, and bone imaging, supported by major urban healthcare centers.

In Europe, the United Kingdom maintains strong nuclear medicine services across public and specialist hospital networks, with emphasis on clinical governance and appropriate-use pathways. Germany is notable for advanced imaging infrastructure, strong academic nuclear medicine programs, and broad SPECT/CT application. France supports structured nuclear medicine practice through specialist centers and national healthcare systems, while Russia has established capabilities in major hospitals and research institutions. Italy and Spain maintain active SPECT utilization in cardiology, oncology, endocrine, neurology, and musculoskeletal imaging, with modernization efforts focused on hybrid systems and workflow efficiency.

China is expanding nuclear medicine capacity through hospital infrastructure growth, specialist training, and rising demand for oncology and cardiovascular diagnostics. India is increasing access to SPECT in metropolitan centers and large hospital networks, driven by growing chronic disease burden and expanding private healthcare investment. Japan demonstrates mature nuclear medicine practice with high standards for imaging quality, aging-population-driven demand, and advanced clinical protocols. Australia supports SPECT through well-regulated nuclear medicine services, strong quality assurance, and access in major healthcare hubs, while South Korea combines advanced medical technology adoption with strong hospital-based imaging capabilities and active clinical research.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated innovation that improves diagnostic confidence, workflow efficiency, and patient safety without increasing operational complexity. Imaging providers can strengthen SPECT programs by investing in hybrid SPECT/CT capabilities where clinically justified, adopting standardized protocols, implementing dose optimization practices, and expanding structured reporting. Institutions should focus on staff training in nuclear medicine technology, radiopharmacy handling, radiation protection, quantitative imaging, and AI-assisted workflow oversight to ensure consistent quality across sites.

Technology developers should design SPECT systems and software that integrate smoothly with hospital information systems, radiology information systems, picture archiving platforms, and electronic health records. AI solutions should be developed with transparent validation, explainable outputs, cybersecurity safeguards, and post-deployment performance monitoring. Radiopharmaceutical stakeholders should focus on reliable production, cold-chain logistics, regulatory compliance, and tracer availability to support continuity of care. Healthcare executives should align SPECT investments with high-impact clinical pathways such as myocardial perfusion imaging, bone metastasis evaluation, parathyroid localization, infection imaging, neuroendocrine tumor assessment, and neurodegenerative disease evaluation. Collaboration among clinicians, physicists, technologists, regulators, and payers is essential to demonstrate clinical value, reduce variability, and expand appropriate access.

Research Methodology

This executive summary is developed through a structured secondary research approach focused on verified, evidence-based sources relevant to Single Photon Emission Computed Tomography. The methodology includes review of clinical practice guidelines, peer-reviewed nuclear medicine literature, regulatory guidance, health technology assessments, radiation safety standards, public health data, hospital imaging workflow documentation, and professional society recommendations. Emphasis is placed on validated clinical applications, technology trends, regulatory considerations, regional healthcare infrastructure, and adoption factors influencing SPECT and SPECT/CT implementation.

The research approach prioritizes triangulation across multiple credible source categories to reduce bias and improve reliability. Clinical insights are assessed based on established diagnostic use cases, appropriate-use guidance, and evidence supporting patient management decisions. Technology insights are evaluated through documented advancements in detector design, reconstruction methods, hybrid imaging, quantification, and artificial intelligence applications. Regional, group, and country-level insights are interpreted through healthcare infrastructure maturity, nuclear medicine capacity, workforce availability, radiopharmaceutical logistics, regulatory frameworks, and disease-burden relevance. The analysis intentionally excludes market sizing, market share, and forecasting to maintain focus on qualitative, data-backed industry intelligence.

Conclusion

Single Photon Emission Computed Tomography continues to play a vital role in modern diagnostic imaging by delivering functional and molecular information that complements anatomical modalities. Its relevance is being reinforced by hybrid SPECT/CT systems, improved detector technologies, quantitative imaging, radiopharmaceutical development, and AI-enabled workflow enhancement. Clinical demand is supported by the persistent burden of cardiovascular disease, cancer, neurological disorders, endocrine conditions, infection and inflammation assessment, and musculoskeletal disease, all of which benefit from targeted functional imaging in selected patient pathways.

The future of SPECT will be defined by its ability to deliver reproducible, efficient, and clinically actionable insights while meeting expectations for radiation safety, cost-effective care, and integrated digital workflows. Regions with mature nuclear medicine infrastructure are moving toward advanced quantification, automation, and evidence-based utilization, while emerging healthcare systems are focused on access, training, and radiopharmaceutical reliability. Organizations that combine technology modernization with rigorous quality management, responsible AI adoption, and patient-centered imaging protocols will be best positioned to strengthen the role of SPECT in precision diagnostics and longitudinal care management.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Single Photon Emission Computed Tomography Market, by Product Type

• 7.1. Introduction
• 7.2. Standalone SPECT Systems
• 7.3. Hybrid Imaging Systems
• 7.4. Portable SPECT Systems

8. Single Photon Emission Computed Tomography Market, by Detector Technology

• 8.1. Introduction
• 8.2. Anger Scintillation Camera Technology
• 8.3. Solid State Detector Technology
• 8.4. Hybrid Detector Technology

9. Single Photon Emission Computed Tomography Market, by Component Type

• 9.1. Introduction
• 9.2. Hardware
  • 9.2.1. Gamma cameras
  • 9.2.2. Detectors
  • 9.2.3. Gantry systems
  • 9.2.4. Collimators
• 9.3. Software
  • 9.3.1. Image Reconstruction Software
  • 9.3.2. Image Analysis Software
  • 9.3.3. Workflow Management Software
• 9.4. Services
  • 9.4.1. Installation services
  • 9.4.2. Maintenance services

10. Single Photon Emission Computed Tomography Market, by Mobility

• 10.1. Introduction
• 10.2. Fixed Spect Systems
• 10.3. Mobile Spect Systems

11. Single Photon Emission Computed Tomography Market, by Patient Type

• 11.1. Introduction
• 11.2. Adult
• 11.3. Pediatric
• 11.4. Geriatric

12. Single Photon Emission Computed Tomography Market, by Application

• 12.1. Introduction
• 12.2. Cardiology
• 12.3. Neurology
• 12.4. Oncology

13. Single Photon Emission Computed Tomography Market, by End User

• 13.1. Introduction
• 13.2. Diagnostic Centers
• 13.3. Hospitals
  • 13.3.1. Private Hospitals
  • 13.3.2. Public Hospitals
• 13.4. Research Institutes

14. Single Photon Emission Computed Tomography Market, by Region

• 14.1. Asia-Pacific
• 14.2. North America
• 14.3. Latin America
• 14.4. Europe
• 14.5. Middle East
• 14.6. Africa

15. Single Photon Emission Computed Tomography Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Single Photon Emission Computed Tomography Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2025
• 17.2. FPNV Positioning Matrix, 2025
• 17.3. Market Concentration Analysis, 2025
  • 17.3.1. Concentration Ratio (CR)
  • 17.3.2. Herfindahl Hirschman Index (HHI)
• 17.4. Recent Developments & Impact Analysis, 2025
• 17.5. Product Portfolio Analysis, 2025
• 17.6. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. Agfa-Gevaert Group
• 18.2. Bracco Imaging S.p.A.
• 18.3. Bruker Corporation
• 18.4. Canon Medical Systems Corporation
• 18.5. Cardinal Health Inc
• 18.6. Curium Pharma
• 18.7. Digirad Corporation
• 18.8. Fujifilm Holdings Corporation
• 18.9. GE HealthCare Technologies Inc
• 18.10. Jubilant Radiopharmacies
• 18.11. Koninklijke Philips N.V.
• 18.12. Kromek Group PLC
• 18.13. Lantheus Medical Imaging Inc
• 18.14. Mediso Ltd
• 18.15. MILabs B.V.
• 18.16. Neusoft Corporation
• 18.17. NorthStar Medical Radioisotopes LLC
• 18.18. Samsung Medison Co. Ltd.
• 18.19. Shimadzu Corporation
• 18.20. Siemens Healthineers AG
• 18.21. Spectrum Dynamics Medical Inc
• 18.22. United Imaging Healthcare Co. Ltd.